| Literature DB >> 26089211 |
Antonio Rodriguez-Poncelas1, Sònia Miravet-Jiménez2, Aina Casellas3, Joan Francesc Barrot-De La Puente4, Josep Franch-Nadal5, Flora López-Simarro2, Manel Mata-Cases6, Xavier Mundet-Tudurí7.
Abstract
BACKGROUND/AIMS: Retinal photography with a non-mydriatic camera is the method currently employed for diabetic retinography (DR) screening. We designed this study in order to evaluate the prevalence and severity of DR, and associated risk factors, in patients with type 2 diabetes (T2DM) screened in Catalan Primary Health Care.Entities:
Keywords: Epidemiology; Retina; Telemedicine
Mesh:
Substances:
Year: 2015 PMID: 26089211 PMCID: PMC4680151 DOI: 10.1136/bjophthalmol-2015-306683
Source DB: PubMed Journal: Br J Ophthalmol ISSN: 0007-1161 Impact factor: 4.638
Figure 1Prevalence of diabetic retinopathy.
Characteristics of patients with and without digital photography
| N (%) | Global | Without DP | With DP | *P value |
|---|---|---|---|---|
| Sex, n (%) | <0.001 | |||
| Male | 180 198 (54.7) | 119 087 (54.0) | 61 111 (56.2) | |
| Female | 149 221 (45.3) | 101 609 (46.0) | 47 612 (43.8) | |
| Age (years) (n=329 419) | 68.6 (11.7) | 69.4 (11.9) | 66.9 (11.0) | <0.001 |
| BMI (kg/m2, SD) (n=329 419) | 30.1 (5.1) | 30.1 (5.2) | 30.2 (5.0) | <0.001 |
| Diabetes time of progress (years) (n=329 419) | 7.6 (5.6) | 7.5 (5.8) | 7.8 (5.1) | <0.001 |
| Age of diabetes diagnosis (n=329 419) | 61.0 (11.4) | 61.9 (11.7) | 59.2 (10.7) | <0.001 |
| A1C (%) (n=263 690) | 7.2 (1.3) | 7.2 (1.3) | 7.2 (1.3) | 0.631 |
| Hypertension, n (%) (n=264 743) | 80.4 | 80.5 | 80.1 | 0.003 |
| SBP (mm Hg) (n=279 030) | 134.8 (13.2) | 135.0 (13.5) | 134.5 (12.5) | <0.001 |
| DBP (mm Hg) (n=279 030) | 75.2 (8.6) | 75.0 (8.8) | 75.6 (8.3) | <0.001 |
| PP (mm Hg) (n=279 030) | 59.6 (12.4) | 60.0 (12.7) | 58.9 (11.9) | <0.001 |
| Non-HDL cholesterol (mg/dL) (n=248 610) | 137.0 (36.9) | 137.0 (37.4) | 136.9 (36.0) | 0.461 |
| Triglycerides (mg/dL) (n=258 046) | 154.5 (102.6) | 153.5 (103.3) | 156.4 (101.2) | <0.001 |
| Creatine (mg/dL) (n=265 898) | 0.9 (0.4) | 0.9 (0.4) | 0.9 (0.3) | <0.001 |
| eGFR (mL/min/1.73 m2) <60, n (%) (n=265 898) | 57 957 (21.8) | 39 431 (22.9) | 18 526 (19.7) | <0.001 |
| UACR (mg/g) (n=149 526) | 41.8 (155.1) | 45.4 (163.4) | 36.1 (141.3) | <0.001 |
*p Value for comparison of groups with Pearson's χ2 test for qualitative variables and ANOVA for the quantitative ones. Values are expressed as n (%) and mean (SD).
A1C, glycated haemoglobin; BMI, body mass index; DBP, diastolic blood pressure; DP, digital photography; eGFR, estimated glomerular filtration ratio; PP, pulse pressure; SBP, systolic blood pressure; UACR, urinary albumin-to-creatine ratio.
Clinical and laboratory characteristics of patients without DR, with NPDR, PDR and DMO
| Global | No DR | NPDR | PDR | DMO | P value* | |
|---|---|---|---|---|---|---|
| N | 108 723 | 95 336 | 12 788 | 400 | 199 | |
| Sex (M), n (%) | 61 111 (56.2) | 53 642 (56.3) | 7137 (55.8) | 216 (54.0) | 116 (58.3) | 0.553 |
| Age (years) (n=108 723) | 66.9 (11.0) | 66.7 (11.0) | 68.5 (10.9) | 71.3 (9.7) | 69.8 (10.9) | <0.001 |
| BMI (Kg/m2) (n=89 610) | 30.2 (5.0) | 30.2 (5.0) | 30.0 (5.1) | 30.1 (4.6) | 29.5 (4.4) | 0.002 |
| Diabetes time of progress (years) | 7.8 (5.1) | 7.5 (4.9) | 9.8 (5.9) | 10.7 (5.8) | 9.6 (5.8) | <0.001 |
| Age of diabetes diagnosis (years) | 59.2 (10.7) | 59.2 (10.6) | 58.6 (11.2) | 60.6 (10.8) | 60.2 (11.4) | <0.001 |
| A1C (%) (n=95 126) | 7.2 (1.3) | 7.2 (1.3) | 7.7 (1.5) | 8.0 (1.6) | 7.7 (1.5) | <0.001 |
| Insulin treatment, n (%) | 18 452 (17.0) | 13 338 (14.0) | 4819 (37.7) | 218 (54.5) | 77 (38.7) | <0.001 |
| Hypertension, n (%) | 87 056 (80.1) | 75 645 (79.3) | 10 869 (85.0) | 364 (91.0) | 178 (89.4) | <0.001 |
| SBP (mm Hg) (n=97 646) | 134.5 (12.5) | 134.1 (12.3) | 136.9 (13.4) | 137.9 (14.2) | 138.9 (14.5) | <0.001 |
| DBP (mm Hg) (n=97 646) | 75.6 (8.3) | 75.7 (8.3) | 74.7 (8.6) | 73.4 (8.7) | 74.3 (8.9) | <0.001 |
| PP (mm Hg) (n=97 646) | 58.9 (11.9) | 58.4 (11.7) | 62.2 (12.8) | 64.5 (12.8) | 64.6 (13.0) | <0.001 |
| Non-HDL cholesterol (mg/dL) | 136.9 (36.0) | 137.5 (35.8) | 132.4 (36.9) | 130.1 (35.3) | 134.9 (37.7) | <0.001 |
| Creatine (mg/dL) (n=93 774) | 0.9 (0.3) | 0.9 (0.3) | 1.0 (0.4) | 1.1 (0.5) | 1.0 (0.9) | <0.001 |
| eGFR (mL/min/1.73 m2), n (%) | <0.001 | |||||
| ≥60 | 75 394 (80.3) | 66 988 (81.1) | 8082 (74.3) | 208 (63.4) | 116 (69.9) | |
| <60 | 18 526 (19.7) | 15 564 (18.9) | 2792 (25.7) | 120 (36.6) | 50 (30.1) | |
| UACR (mg/g), n (%) | <0.001 | |||||
| <30 | 48 860 (83.0) | 43 655 (84.5) | 5029 (73.0) | 118 (62.1) | 58 (59.2) | |
| 30–299 | 8692 (14.8) | 7081 (13.7) | 1519 (22.1) | 58 (30.5) | 34 (34.7) | |
| ≥300 | 1294 (2.2) | 936 (1.8) | 338 (4.9) | 14 (7.4) | 6 (6.1) |
*p Value for comparison of groups with Pearson's χ2 test for qualitative variables and ANOVA for the quantitative ones.
Values are expressed as n (%) and mean (SD).
A1C, glycated haemoglobin; BMI, body mass index; DBP, diastolic blood pressure; DMO, macular oedema; DR, diabetic retinopathy; eGFR, estimated glomerular filtration ratio; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; PP, pulse pressure; SBP, systolic blood pressure; UACR, urinary albumin-to-creatine ratio.
Patients with any kind of diabetic retinopathy and associated risk factors
| Any DR | Mild-NPDR | Moderate-NPDR | Severe-NPDR | PDR | DMO | *P value | |
|---|---|---|---|---|---|---|---|
| Sex | 0.001 | ||||||
| Male | 7469 (12.2) | 4464 (7.29) | 2092 (3.42) | 581 (0.95) | 216 (0.35) | 116 (0.19) | |
| Female | 5918 (12.4) | 3680 (7.71) | 1608 (3.36) | 363 (0.76) | 184 (0.38) | 83 (0.17) | |
| Total | 13 387 (12.3) | 8144 (7.48) | 3700 (3.39) | 944 (0.86) | 400 (0.36) | 199 (0.18) | |
| Diabetes time duration (years) | <0.001 | ||||||
| <5 | 2420 (6.9) | 1580 (4.50) | 607 (1.73) | 146 (0.42) | 47 (0.14) | 40 (0.11) | |
| 5–9 | 5907 (12.5) | 3633 (7.68) | 1623 (3.44) | 396 (0.84) | 170 (0.36) | 85 (0.18) | |
| 10–15 | 3083 (17.2) | 1847 (10.31) | 851 (4.74) | 221 (1.23) | 121 (0.68) | 43 (0.24) | |
| >15 | 1977 (23.7) | 1084 (12.99) | 619 (7.43) | 181 (2.17) | 62 (0.74) | 31 (0.37) | |
| A1C (%) | <0.001 | ||||||
| ≤7.0 | 4360 (8.4) | 2912 (5.61) | 1042 (2.01) | 236 (0.45) | 99 (0.19) | 71 (0.14) | |
| >7.0 to <7.9 | 3193 (13.3) | 1933 (8.05) | 918 (3.82) | 215 (0.90) | 92 (0.38) | 35 (0.15) | |
| 8 to 9 | 1868 (18.4) | 1064 (10.47) | 560 (5.52) | 150 (1.48) | 67 (0.66) | 27 (0.27) | |
| >9 | 2026 (22.9) | 1084 (12.25) | 650 (7.35) | 191 (2.16) | 71 (0.80) | 30 (0.34) | |
| Insulin treatment | <0.001 | ||||||
| No | 8273 (9.2) | 5370 (5.97) | 2146 (2.39) | 453 (0.50) | 182 (0.20) | 122 (0.14) | |
| Yes | 5114 (27.7) | 2774 (15.03) | 1554 (8.42) | 491 (2.65) | 218 (1.18) | 77 (0.42) | |
| Smoking Status | 0.182 | ||||||
| Smoker | 1573 (10.7) | 968 (6.58) | 441 (3.00) | 104 (0.71) | 45 (0.31) | 15 (0.10) | |
| Past-smoker | 3486 (11.9) | 2085 (7.13) | 991 (3.38) | 264 (0.90) | 89 (0.30) | 54 (0.18) | |
| Never-smoker | 8274 (12.9) | 5060 (7.89) | 2252 (3.51) | 568 (0.89) | 264 (0.41) | 130 (0.20) | |
| Hypertension | <0.001 | ||||||
| No | 1976 (9.1) | 1275 (5.87) | 516 (2.38) | 128 (0.58) | 36 (0.17) | 21 (0.10) | |
| Yes | 11 411 (13.1) | 6869 (7.89) | 3184 (3.66) | 816 (0.93) | 364 (0.42) | 178 (0.20) | |
| Blood pressure (mm Hg) | <0.001 | ||||||
| ≥140/90 | 4487 (15.4) | 2620 (8.99) | 1316 (4.52) | 338 (1.16) | 143 (0.49) | 70 (0.24) | |
| <140/90 | 7490 (10.9) | 4664 (6.79) | 2007 (2.92) | 484 (0.70) | 224 (0.33) | 111 (0.16) | |
| No HDL-cholesterol (mmol/L) | 0.272 | ||||||
| ≥3.3 | 2353 (10.5) | 1437 (6.41) | 632 (2.82) | 183 (0.82) | 65 (0.29) | 36 (0.16) | |
| <3.3 | 8390 (12.6) | 5105 (7.67) | 2366 (3.55) | 559 (0.84) | 247 (0.37) | 113 (0.17) |
*p Value for group comparison with Pearson's χ2 test for qualitative variables and ANOVA for the quantitative ones.
A1C, glycated haemoglobin; DMO, diabetic macular oedema; DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.